Compare GEO & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | TSHA |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.2B |
| IPO Year | 1996 | 2020 |
| Metric | GEO | TSHA |
|---|---|---|
| Price | $14.55 | $4.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $39.67 | $10.56 |
| AVG Volume (30 Days) | ★ 3.0M | 2.2M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | 62.50 |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $2,263,420,000.00 | $8,333,000.00 |
| Revenue This Year | $13.74 | N/A |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $12.51 | $1.13 |
| 52 Week High | $32.09 | $6.02 |
| Indicator | GEO | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 43.04 |
| Support Level | $14.27 | $4.39 |
| Resistance Level | $15.54 | $5.16 |
| Average True Range (ATR) | 0.72 | 0.21 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 59.03 | 18.83 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.